CYP2C9 and VKORC1 gene polymorphism and acenocoumarol anticoagulant activity in Russian patients at high risk of thromboembolic complications

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 3, 2011, Pages 7-10

  Sychev, D A ^a,b,c   Ignatiev, I V ^c   Kropacheva, E S ^d   Emel'yanov, N V ^c   Milovanova, V V ^c   Naumova, Yu A ^a   Kosovskaya, A V ^a   Dobrovol'skv, O B ^d   Tashenova, A I ^a   Panchenko, E P ^d   Kukesl, V G ^b,c  

^a Clinical Pharmacology Branch   (Russian Federation)

^b I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^c Clinical Expertise of Medicinal Products   (Russian Federation)

^d INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Anticoagulants; Cytochrome p 450; Genetic polymorphism; Pharmacogenetics

Indexed keywords

EID: 79955877207     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Talmage J. B. Arterial Embolism and Thrombosis. Arterial Embolism and Thrombosis. In: Talmage J. B., ed.: MDGuidelines; 2009.
2. Torn M., Bollen W. L., van der Meer F. J. et al. Risks of oral anticoagulant therapy with increasing age. Arch. Intern. Med. 2005;165:1527-1532. (Pubitemid 41058034)
3. Kamali F. Genetic influences on the response to warfarin. Curr. Opin. Hematol. 2006;13:357-361. (Pubitemid 44168457)
4. Millican E. A., Lenzmi P. A., Milligan P. E. et al. Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 2007;110:1511-1515. (Pubitemid 47443966)
5. Michaud V., VanierM. C, Brouillette D. et al. Turgeon J. Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clin. Pharmacol. Ther. 2008;83:740-748. (Pubitemid 351556023)
6. Geisen C, Watzka M., Sittinger K. et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 2005;94:773-779. (Pubitemid 41489236)
7. Marcatos C. N., Grouzi E., Politou M. et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 2008;9:1631-1638.
8. Rettie A. E., Farm F. M., Beri N. G. et al. A case study of acenocoumarol sensitivity and genotype-phenotype discordancy explained by combinations of polymorphisms in VKORC1 and CYP2C9. Br. J. Clin. Pharmacol. 2006;62:617-620. (Pubitemid 44571584)
9. Schalekamp T., Brasse B. P., Roijers J. F. et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin. Pharmacol. Ther. 2006;80:13-22. (Pubitemid 43964915)